🔴 Ionis Pharmaceuticals is trading 4.8% down today without a new company-specific catalyst

Ionis Pharmaceuticals is trading at $58.39, down 4.79%, without a new company-specific catalyst identified for September 3, 2026.

• Ionis’s investor-conference announcement is routine and concerns appearances on September 10 and September 16.
• The decline contrasts with broader biotechnology strength: XBI is up 2.75%, and major U.S. indexes are also higher.
• Recent pressure reflects investor concerns after the July eplontersen Phase 3 trial failure, not a new September 3 event.